The acquisition of Acreage Holdings provides a path for Canopy Growth to enter the U.S. market upon eventual federal legalization of cannabis production and sale, Benchmark analyst Mike Hickey tells investors in a research note. The analyst estimates the U.S. cannabis market is 10 times the Canadian market. He keeps a Buy rating on Canopy Growth shares with a C$100 price target. However, cannabis sales data from Canada Health suggests a slow start to Q1, Hickey points out. As such, he expects the company to report fiscal Q4 sales of C$93M, below the consensus of C$98M. Canopy Growth in early trading is up 2% to $45.52 after GMP Securities upgraded the shares to Buy.